AKT1 and neoplasm: The signaling proteins AKT, MEK and ERK mediate critical tumor cell apoptosis and proliferation pathways [20–23], so we next investigated whether the inhibitory effects of poly-ICLC/Sorafenib combinatorial therapy could be associated with modulation of these key pathways.